Clinical trial · Interventional
Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial PNETs and metastatic PNETs.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| High Risk Supratentorial PNET | — | UNRESOLVED | — |
| Metastatic Medulloblastoma | Medulloblastoma | CURATED_BROADER | 0.80 |
| Metastatic PNET | Primitive Neuroectodermal Tumor | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 24 Gy | Radiation | — | UNRESOLVED |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Vincristine | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Reduced radiation with concurrent chemotherapy
- description
- Reduced dose craniospinal radiation with concurrent carboplatin and vincristine administration
- interventionNames
- Drug: Carboplatin
- Drug: Vincristine
- Radiation: 24 Gy
Primary outcomes (5)
- measure
- Event-free Survival
- timeFrame
- Up to 60 months.
- description
- MRIs of the head and spine. Number of participants with event free survival at 60 months is reported.
- measure
- Overall Survival
- timeFrame
- up to 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Age greater than 3 years and less than 25 years * Patients with classic histology or desmoplastic histology metastatic medulloblastoma by histological diagnosis and by head and spine MRI. * Patients with high-risk supratentorial, non-metastatic, PNET * Patients with metastatic PNET * Newly diagnosed patients who have not received prior therapy, with the exception of one short course of emergent chemotherapy in newly presenting patients with neurological compromise per provider decision * Only patients who are expected to survive at least 6 weeks will be eligible for this study. Exclusion Criteria: * Patients who are pregnant may not be treated on this study * Patients with anaplastic histology
References
Publications (0)
Data not yet available